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 ECMO could provide an alternative solution for treating patients with respiratory or 
cardiac failure. 
 The pores in the membrane wall play a more significant role in determining the 
resistance to plasma leakage than the surface pores. 
 PMP membrane oxygenators can be used for long-term operation. 
 Surface modification can successfully improve membrane biocompatibility. 
 
Abstract. Extracorporeal blood oxygenation has become an alternative to supply 
O2 and remove CO2 from the bloodstream, especially when mechanical ventilation 
provides insufficient oxygenation. The use of a membrane oxygenator offers the 
advantage of lower airway pressure than a mechanical ventilator to deliver oxygen 
to the patient’s blood. However, research and development are still needed to find 
appropriate membrane materials, module configuration, and to optimize 
hydrodynamic conditions for achieving high efficient gas transfer and excellent 
biocompatibility of the membrane oxygenator. This review aims to provide a 
comprehensive description of the basic principle of the membrane oxygenator and 
its development. It also discusses the role and challenges in the use of membrane 
oxygenators for extracorporeal oxygenation on respiratory and cardiac failure 
patients. 
Keywords: blood oxygenation; COVID-19; gas transfer; membrane oxygenator; 
respiratory. 
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1 Introduction 
Mechanical ventilation is widely used as a primary management tool for patients 
with respiratory failure to supply O2 and remove CO2 from the bloodstream. It is 
the medical term for artificial ventilation where mechanical means are used to 
assist or replace spontaneous breathing. The oxygen is forced into the lungs 
through a tube inserted into the trachea. The ventilator pumps oxygen and the 
lungs inflate to mimic the process of breathing. The essential goals of ventilatory 
support to achieve safe treatment are stabilizing hydrodynamic, patient-ventilator 
synchrony, preserving muscle strength, minimizing dynamic hyperinflation, and 
limiting tissue damage [1,2]. Lung injury can occur due to high airway pressure 
and oxygen concentration without excessive lung strain or damage due to 
restricted chest wall movement [1]. 
When mechanical ventilation is not sufficient to provide oxygenation, 
extracorporeal blood oxygenation is an alternative rescue therapy with beneficial 
results [3]. Extracorporeal membrane oxygenation (ECMO) uses a 
semipermeable membrane to facilitate the transfer of oxygen to the blood of the 
patient. In a membrane oxygenator, gas exchange between the blood and gas 
streams occurs with non-dispersive contact, preventing the entrainment of the 
blood to the gas stream [4]. Since the gas exchange occurs in non-dispersive 
contact, the blood and the gas streams can be controlled independently to prevent 
damage to blood constituents. In addition, the membrane has a high packing 
density [5-8], resulting in a compact membrane oxygenator. Compared to a 
mechanical ventilator, the ECMO system provides an adequate amount of oxygen 
(O2) to the bloodstream without high pressure, which also simultaneously 
removes carbon dioxide (CO2). There are two types of commercially available 
ECMO systems, namely venous-arterial (VA) ECMO systems and venous-
venous (VV) ECMO systems. VA-ECMO is used for patients with various 
etiologies of cardiogenic shock and entails either central or peripheral cannulation 
[9]. Meanwhile, VV-ECMO is used mainly for patients with severe respiratory 
failure [10]. A part that plays a vital role in ECMO systems is the membrane 
oxygenator, which acts as an artificial lung for gas exchange to maintain 
physiologic O2 and CO2 levels in the blood [11]. The membrane oxygenator has 
to meet a number of criteria, including high gas transfer performance, high 
mechanical property, low plasma leakage, high anti-thrombogenic properties, 
low protein adsorption, and low platelet adhesion [12-14]. 
Membrane oxygenators are usually fabricated using polymeric materials, such as 
polysulfone [15], polyurethane [16], polypropylene [17], polyimide [18], and 
silicon [19-22]. Among these polymers, non-porous silicon-based hollow fiber is 
used in commercial ECMO systems due to its ability to avoid plasma leakage 
during the long time of extracorporeal circulation. Recently, a silicone hollow 
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fiber membrane with ultra-thin wall thickness has been developed, which exhibits 
high oxygen and carbon dioxide transfer rates [5]. During the ECMO treatment, 
clot formation on the membrane surface is the main challenge due to interaction 
of the vascular endothelium with plasma proteins and platelets. Surface 
modification of the membrane oxygenator with anticoagulants, such as heparin 
or hydrophilization of the membrane surface, has been proposed to reduce clot 
formation [16,17,23]. 
In the last 20 years, numerous scientific studies have focused on membrane 
oxygenator development and several applications have been published (Figure 
1(a)). Most of these articles were published in medical and health or biomedical 
journals, followed by engineering and biochemistry journals. In 2009, the 
application of membrane oxygenators was further increased to treat severe acute 
respiratory distress syndrome (ARDS) patients during the influenza A (H1N1) 
and SARS (Severe Acute Respiratory Syndrome) pandemic. Since 
polymethylpentene (PMP) oxygenators were developed in the same year as 
bearingless centrifugal pumps and better cannula technology, the number of 
research articles on the application of membrane oxygenator in ECMO systems 
increased significantly [24]. Recently, Coronavirus Disease 2019 (COVID-19) 
has spread in more than 200 countries and infected more than 140 million people 
in the world, with more than 3,000,000 deaths [25].  
COVID-19 is caused by a novel SARS-CoV-2 virus, which enters the human 
body through the respiratory tract, oral mucosa, and conjunctival epithelium 
[26,27]. Most COVID-19 patients suffer worsening breathing difficulties due to 
respiratory failure and acute respiratory distress syndrome (ARDS) [28,29]. 
Several research papers on the role of ECMO in COVID-19 patient treatment 
have been published.  Based on the number of publications in the last 20 years, 
the study on ECMO applications for patients with respiratory or lung failure is 
higher than those for cardiac failure (Figure 1b).  
Previously, several reviews have discussed the ECMO and its importance during 
the COVID-19 pandemic. Alentiev and co-workers [30] elaborated on the 
progress of ECMO technology by discussing membrane materials, methods for 
increasing compatibility, and rational approaches for designing the membrane 
contactor. Savarimuthu, et al. [31] emphasized that the use of an ECMO should 
be prioritized for critically ill patients that have been selected carefully due to the 
limited number of ECMO units.  
They also provide the prospect of ECMO playing an important role in the near 
future for combatting COVID-19. This paper aims to provide a comprehensive 
review of a wide spectrum of membrane oxygenators and their application in 
extracorporeal blood oxygenation. This includes the fundamental background, 
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system and materials’ development, and the crucial role of the membrane 
oxygenator in ECMO systems during the treatment of patients with respiratory 
and cardiac failure. 
 
Figure 1 Number of publications per year: (a) related to membrane oxygenator 
or extracorporeal membrane oxygenation (ECMO), and (b) its applications. The 
number of publications was collected by using Elsevier’s Scopus database with 
the query ‘TITLE (membrane oxygenator or extracorporeal membrane 
oxygenation)’; attn: 6th Dec 2020.  
2 Fundamental Background of Membrane Oxygenator 
2.1 Blood Oxygenation in ECMO 
An ECMO module has two compartments, which are separated by a 
semipermeable membrane. The patient’s blood flows into the first compartment 
or the shell side of the module, while a rich-oxygen gas passes through the second 
or lumen side of a hollow fiber (HF) membrane. The membrane serves as a 
contactor and facilitates the gas exchange between the blood and the fresh gas, 
where both oxygen delivery to the blood and carbon dioxide removal from the 
blood occur [32,33]. The VV-ECMO process replaces the native lung function. 
Unlike a conventional bubble oxygenator, an ECMO system prevents direct 
contact between the blood and the fresh gas, allowing one to optimize both 
streams independently and minimizing blood trauma. 
The gas transfer between the blood and the gas through the membrane is a crucial 
step in the oxygenation process. A natural lung membrane has a surface area of 
150 m2 [34] or 70 m2 [35], is 1 to 3 μm thick, and has a surface/blood volume 
ratio of 300 cm-1, leading to 3,000 mL/min oxygenation and carbon dioxide 
removal. In contrast, an ECMO membrane has a lower surface area (<4 m2), a 
thicker membrane (10 to 30 μm), and a lower packing density (30 cm-1) than a 
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natural lung. Consequently, an ECMO can only carry a maximum gas exchange 
of 250–200 mL/min [34].  
Aside from the gas diffusion process, plasma leakage and activation of 
coagulation  are significant concerns in ECMOs [34]. Constant contact of the 
blood with non-biological artificial material, i.e. the membrane oxygenator 
material may trigger coagulation activation, resulting in thrombosis, bleeding, 
and device problems during oxygenation [36]. 
ECMO generally  uses two types of membranes, dense (or non-porous) and 
microporous membranes, as selective barrier. A solution-diffusion mechanism 
usually governs the gas transport in the dense membrane. The flux of gas through 
the membrane, Ji, is expressed by Fick’s law [37]: 
 𝐽 =  −𝐷  (1) 
where Ci is the concentration of species i in the membrane, D is the diffusion 
coefficient of species i in the membrane, and x is the gas flow direction across the 
membrane. According to Henry’s law, the gas concentration in the membrane is 
proportional to pressure p and gas solubility S in the membrane (C = S p). This is 
based on the assumption that the gas solubility in the polymer is very low. The 
product of D x S is known as the gas permeability (P). By introducing Pi, Eq. (1) 
can be integrated and rewritten as [37]: 
 𝐽 = (𝑝 − 𝑝 ) (2) 
where l is the membrane thickness, pf and pp are the pressure in the feed and 
permeate sides, respectively. According to this mechanism, selective transport 
occurs for gases with different permeability. For ECMOs, the membrane should 
allow high permeation of O2 and CO2 during the oxygenation while retaining 
other gasses like N2 in the fresh gas.  
The dense homogenous membrane exhibits high mass transfer resistance due to 
the small membrane pores. Therefore, a microporous hydrophobic membrane has 
been introduced [38]. The flux of the gas into the liquid stream, J, in microporous 
membranes is defined as [39]: 
 𝐽 = 𝐾 𝐶 (3) 
where C is the overall concentration difference across the membrane and K is 
the overall average mass-transfer coefficient. The mass-transfer coefficient can 
be determined experimentally by measuring the gas concentration in the liquid 
phase. The average mass-transfer coefficient is then expressed by [39]: 
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In Eq. (4), A is the membrane surface area, C is the gas concentration, C0 is the 
initial gas concentration, C* is the equilibrium gas concentration, and Q is the 
volumetric flow rate of the liquid. It should be noted that the main resistance to 
gas transfer in the blood oxygenation using microporous membranes is the liquid 
side concentration boundary layer. Hence, K, the overall average mass transfer 
coefficient can be represented by the liquid side mass-transfer coefficient. Here, 
the hydrodynamic condition is one of the main parameters that affect the 
efficiency of mass transfer. 
2.2 Membranes and Module Design for ECMO 
ECMO requires a hemocompatible membrane that can perform efficient gas 
exchange [40]. Various membrane types used in membrane oxygenators are 
illustrated in Figure 2(a). Non-porous membranes can be free from plasma 
leakage since they have very small pores, preventing the intrusion of blood cells 
[41], however, they are usually limited by low gas permeability [42]. This poses 
another challenge, because the larger membrane area must achieve sufficient gas 
transfer to the patient’s blood. Therefore, the recent development of non-porous 
membranes for ECMO application is directed at obtaining highly permeable 
membranes (discussed in Section 3). 
For ECMOs that use a microporous membrane, a hydrophobic membrane 
material is required to prevent liquid penetrating into membrane pores. This is 
because liquid penetration will wet the membrane, leading to a dramatic decrease 
in the gas exchange rate and increased mass-transfer resistance (see Figure 2(b)) 
[38]. As a result, the long-term blood oxygenation performance will be 
compromised. In addition to the membrane’s hydrophobic/hydrophilic property, 
a recent study has revealed that liquid infiltration is related to the pore size in the 
membrane wall [38].  
This study then suggests that the membrane pore size distribution and the 
presence of surfactants in the patient’s blood determines the membrane’s 
resistance to plasma leakage. Lastly, membrane leaking and plasma leakage could 
also occur because of the formation of a hydrophilic surface at the membrane 
pore openings by blood phospholipids [43]. The hydrophilic surface allows 
plasma to infiltrate the membrane pores, leading to further formation of a 
hydrophilic surface along the pore walls, which leads to membrane wetting 
[44,45]. Increasing the gas flow rate can be used as a countermeasure, but this 
risks introducing a gas embolism in the bloodstream [43]. 
Based on the module design, membrane oxygenators can be classified into three 
types, i.e. parallel-plate, spiral-wound (cylindrical), and HF membrane 
oxygenators. In the parallel-plate type, the flat-sheet membranes are separated by 
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screens. This is the simplest arrangement, but the diffusion is limited. In the 
spiral-wound type, the flat-sheet membranes are wrapped around a central 
cylinder [46,47], in which the blood flows parallel to the axis of the cylinder 
between the membrane folds, while oxygen flows through the cylinder. The latter 
type has the advantage of the best flow control [30], where the blood can flow 
inside the fiber or outside the fiber. In addition, there are several option for 
optimizing the flow direction and fiber arrangement. 
 
Figure 2 Membrane types and wetting in membrane oxygenator: (a) various 
membrane types used for membrane oxygenator, (b) wetting decreases the gas 
transfer rate significantly (reprinted with permission from [48], © 2012 John 
Wiley and Sons; the plasma leakage in the inserted figure is from this work). 
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In 2005, Wickramasinghe, et al. [39] reported the mass-transfer and friction-
factor correlations to predict the gas transfer rate and pressure loss of blood in 
microporous HF and flat-sheet membrane oxygenators. By considering the 
average shear stress of the blood (5-20 Pa), the shear-thinning behavior of blood 
was taken into account using the Generalized Graetz, Reynolds, and Schmidt 
numbers. Meanwhile, a mass-transfer enhancement factor based on film theory 
was used to capture the role of the oxygen-hemoglobin reaction, which occurs in 
real conditions.  
Both experimental and numerical simulations were carried out using blood analog 
fluids, i.e. Newtonian and non-Newtonian fluids and bovine blood. For the flat-
sheet membrane module, the mass-transfer correlation is defined by the Graetz 
(Gr) and Sherwood (Sh) numbers (see Figure 3(a)): 
 Sh = 
( )
    (5) 
 Sh = 0.5 Gr (0.5 < Gr < 10) (6) 
 Sh = 3.0 Gr0.33 (10 < Gr < 500) (7) 
where B is the average half-thickness of the rectangular channels, D is the 
diffusion coefficient of O2, and Gr is a function of module geometry (thickness 
and length of the channel), the diffusion coefficient of the gas, and liquid velocity. 
For microporous HF membrane, the mass-transfer correlation is defined by 
dimensionless numbers (the Sherwood, Reynolds, and Schmidt numbers, see 
Figure 3(b)): 
 Sh = 0.8 Re0.59Sc0.33 (8) 
According to these equations, the efficiency of the oxygen transfer in an ECMO 
not only relies on the membrane’s properties but also on the module design and 
the hydrodynamic conditions. The results show that the Sherwood number is 
significantly affected by the liquid flow rate.  
The concentration of the liquid boundary layer limits the mass transfer, which 
applies to all fluid types used. This issue is typically addressed by placing a 
passive mixing unit in the ECMO module so that the liquid boundary layer can 
be disrupted. Increasing the liquid flow rate leads to improved oxygen transfer, 
but increases the risk of pressure loss. Furthermore, the oxygen transfer rate and 
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Figure 3 Membrane oxygenator modules: (a) Sh vs. Gr of flat sheet module, (b) 
Sh/Sc1/3 vs. Re of hollow fiber module (reprinted with permission from [39], 
© 2005 John Wiley and Sons) 
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3 Recent Development of Membrane Oxygenators 
The ECMO has been introduced in 1944 when Kolff & Berk [50,51] came up 
with the idea to add a protective membrane between the blood and the air in 
extracorporeal oxygenators to decrease the potential of blood trauma inherent in 
direct-contact oxygenators. The emphasis in early membrane oxygenator 
development was on finding suitable biomaterials. However, most biomaterials 
had low gas exchange performance and poor mechanical properties, thus limiting 
the development of membrane oxygenators [52].  
In the 1950s, Clowes investigated polyethylene as the oxygenator membrane 
material [46,53]. The polyethylene membrane had good mechanical properties 
but relatively low permeability. In the recent development of membrane 
oxygenators for application in ECMOs, silicone, polypropylene (PP), and 
polymethylpentene (PMP) have been studied predominantly. Membrane 
oxygenators based on these materials are individually reviewed in this section.  
3.1 Silicone-based Membrane Oxygenators 
Silicone is an attractive material for medical devices such as membrane 
oxygenators because of its excellent biocompatibility [54]. In addition, since the 
silicone membrane is typically homogenous, plasma leakage can be avoided. 
However, it is necessary to minimize membrane resistance to enhance the gas 
transfer rate and, on the other hand, it is quite challenging to fabricate thin-walled 
silicone HFs because of the poor mechanical strength of conventional silicone. 
Researchers from Baylor College of Medicine and Fuji Systems Corporation have 
developed a fine silicone HF membrane oxygenator for ECMOs. In 1996, as 
reported by Funakubo, et al. [55], a novel silicone material was developed using 
methylvinylsiloxane as the base polymer, vinyl resin, and hydrogen siloxane. The 
new silicone has sufficient mechanical strength with a wall thickness that is 
approximately half that of a conventional one. As a result, fibers with a surface 
area of 2 m2 exhibited a high O2 and CO2 rate of 195 ml/min and 165 ml/min, 
respectively, at a blood flow rate of 3 L/min, which are values comparable to 
those of a microporous membrane oxygenator. Moreover, with a much smaller 
surface area, its performance was similar to that of the silicone sheet oxygenator 
[56].  
A preclinical evaluation showed that the silicone HFs should be considered for 
one week of ECMO application [57]. A two-week long-term experiment showed 
that the silicone HFs exhibited excellent efficiency, with less blood trauma, but 
further improvement was required to prevent the occurrence of hemolysis [58]. 
In a more recent study, it was revealed that a silicone HF-type module had a 
higher gas transfer rate than a silicone coil-type module [59].  
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A different way to reduce the gas transfer resistance has been proposed by 
Kachab, et al. [60]. Mimicking the bee comb structure, they fabricated a hollow 
silicone sphere. In the presence of microspheres, gas can diffuse easily, resulting 
in a higher gas transfer rate. Other studies used a silicone micropore membrane 
as the support structure for a thin layer of gas-permeable polydimethylsiloxane 
(PDMS) [19,42]. The membrane had an oxygen transfer rate of 0.03 mL/min at a 
liquid flow rate of 10 mL/min with a membrane area of 6.5 x 10-4 m2 [42]. Gas 
transfer performances of membrane oxygenators based on silicone material are 
summarized in Table 1.  
3.2 Polypropylene-based Membrane Oxygenators 
Polypropylene (PP) membrane oxygenators for ECMO systems have been 
reported since the 1980s [61,62]. The adoption of microporous PP was able to 
reduce coagulation issues associated with silicone [43]. In addition, PP membrane 
oxygenators offer high gas transfer rates, low priming volume, and low 
resistance. 
Fried & Bell-Thomson [63] compared the performance of a PP oxygenator 
configured with a flat sheet and an HF (PPHF). They reported that the PPHF 
oxygenator showed a superior trade-off between factors such as diffusion 
distance, surface area, priming volume, and blood flow rate. Besides that, the 
flow configuration also affects the efficiency of the gas transfer. In an HF 
membrane oxygenator where the blood flows inside the fibers, it is possible to 
create laminar blood flow without diffusion limitations. However, blood flow 
inside the fibers can generate an increase in the hydrodynamic resistance of the 
channels, which could lead to an increase in the pressure differential in the 
oxygenator.  
Meanwhile, in an HF arrangement where the blood flows on the outside and gas 
flows on the inside of the fibers, it is possible to control the packing of the fibers 
for the creation of small-thickness channels with a turbulent blood flow [30]. The 
turbulent blood flow leads to an intensification of the convective mass transfer, 
thus increasing the efficiency of the gas transfer. Another study revealed that 
based on theory for tube banks, different PP fiber arrangements (parallel or 
crossed) resulted in a different mass transfer performance [64].  
Even though a PPHF membrane oxygenator is able to provide high gas transfer 
performance, it is not appropriate for use over prolonged periods because of the 
wetting phenomenon [43]. As can be seen in Table 1, PPHF membrane 
oxygenators have a very short operation life. To overcome this problem, efforts 
have been made to modify the structure of the PPHF membrane from 
microporous to non-microporous by silicone coating [62]. The study by Shimono, 
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et al. [65] reported that a silicone coated PPHF oxygenator is more durable and 
offers greater gas transfer capabilities than an uncoated PPHF oxygenator. The 
silicone layer could reduce the contact activation of the oxygenator due to its 
good biocompatibility and complete prevention of contact between blood and 
gas. 
3.3 Polymethylpentene-based Membrane Oxygenator 
In the early 2000s, a new generation of polymethylpentene (PMP) membrane 
oxygenators has been introduced to avoid complications linked to HF 
oxygenators, such as plasma leakage. Different from PPHFs, which are typically 
microporous, PMPHFs have an asymmetric pore structure with a dense outer skin 
that provides complete physical separation between the blood and the gas phases, 
thus avoiding plasma leakage [66,67]. In addition, the asymmetric structure of 
the PMPHF also allows for efficient gas exchange to take place for extended 
periods [68,69]. 
Table 1 Gas transfer performance of silicone-based, PP, and PMP membrane 
oxygenators. 
 
a in vitro study; b one-week ex vivo experiment; c two-week ex vivo experiment. 
*module type: HF – hollow fiber; HSF – hollow sphere fiber; ** manufacturer 
Thiara, et al. [70] evaluated the performance of PP and PMP-based membrane 
oxygenators. The results showed that the lifespan of the oxygenators was 
significantly longer for PMP than for PP membrane oxygenators. In addition, 
plasma leakage was observed in the PP-based oxygenators but did not appear in 
PMP-based oxygenators. This is because PP fibers have a microporous structure, 
while PMP fibers are covered with a dense but very thin outer skin. Therefore, 
PMP membranes have a longer operating life than PP membranes. Furthermore, 
gas permeability for oxygen and carbon dioxide in PMP membranes is excellent, 
with the gas exchange capability remaining equivalent to that of microporous 
membranes [66]. 
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In commercially available HF membrane oxygenators, PP microporous 
membranes are mainly used for short-term operation, while PMP non-porous 
membranes can be used for long-term operation. The main characteristics of 
commercial PP and PMP membrane oxygenators are presented in Table 1. It can 
be seen that PP membrane oxygenators are only able to survive up to 6 hours. 
Meanwhile, the operation life of PMP membrane oxygenators varies from 5 to 30 
days. 
3.4 Surface Modification of Membrane Oxygenator 
To improve the biocompatibility of the membrane oxygenator, the existing 
membrane surface can be modified with biocompatible materials. One of the most 
widely used methods is the covalent binding of heparin molecules with the 
membrane surface [79]. It has been found that a heparin coating could decrease 
the activation of platelets and also possesses anti-inflammatory properties 
[17,30,80]. A heparin coating can also decrease thrombin generation by binding 
to circulating antithrombin [36]. 
Zheng, et al. [81] compared different materials, i.e. acrylic acid with heparin 
(AA-Hep), 2-methacryloyloxyethyl phosphorylcholine (MPC), and collagen, to 
study their biocompatibility. A series of low-temperature plasma treatments 
(LTPT) was used for grafting onto the polysulfone HF membrane. It was found 
that grafting with AA-Hep provided the best hemocompatibility, indicated by the 
lowest protein adsorption, which was consistent with the platelet adhesion 
evaluation that was done. Moreover, the AA-Hep-modified PSF could maintain 
a high gas transfer rate compared to the unmodified PSF. However, heparin 
exposure during long-term ECMO can lead to heparin-induced thrombocytopenia 
(HIT) [82,83]. Therefore, a biomimetic coating with alternative materials is 
encouraged.   
A bioline coating has been used to imitate human endothelial tissue. This reagent 
plays an important role in decreasing the interaction of clotting factors with the 
plastic tubing, thus leading to less activation of the coagulation cascade. Daniel 
and co-workers [67] reported that a bioline coating on a PMP membrane 
oxygenator could reduce the heparin required by patients. Another option is a 
phosphorylcholine coating, as used by Agati, et al. [84], to improve the 
hemocompatibility of a PMP membrane oxygenator. It was observed that neither 
plasma leakage nor device failure occurred in the PMP oxygenators after 105 
hours of operation. A great improvement in hemocompatibility with high stability 
was then successfully obtained by using poly(MPC-co-BMA-co-TSMA)(PMBT) 
coating [85]. The cross-linkable PMBT film formed on the membrane surface 
exhibits strong resistance to protein adsorption as well as platelet adhesion. As a 
result, no adhered thrombus was observed on the PMBT-coated membrane 
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surface, while a dense thrombus layer covered the bare membrane. MPC coating 
on the PMP membrane oxygenator also reduced the protein and platelet 
interaction on the membrane surface [86]. Studies on biocompatibility 
modification of membrane oxygenators are summarized in Table 2. 
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TPX – poly(4-methyl-1-pentene); PMP – polymethyl pentene; PEG – polyethylene glycol; 
MPC – 2-methacryloyloxyethyl phosphorylcholine; PMBT – poly(MPC-co-BMA-co-TSMA); 
4 ECMO Applications 
Registration of the use of ECMOs across the world is organized by an 
international non-profit consortium called the Extracorporeal Life Support 
Organization (ELSO). Members of this consortium are known as ECMO centers. 
A steady increase in the establishment of ELSO-registered ECMO centers began 
about a decade ago, dominated by the North American region. To date, ECMO 
centers have spread in five regions, i.e. North America (2 countries), Latin 
America (26 countries), Asia Pacific (11 countries), South and West Asia, and 
Africa (12 countries). 
ECMO systems have been applied for treating patients with respiratory or cardiac 
failure. The use of ECMOs for both conditions is discussed below. Besides that, 
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the role of ECMOs in treating COVID-19 patients is discussed separately in the 
last part of this section.  
4.1 ECMO for Respiratory Failure 
Respiratory failure occurs when the respiratory system fails to perform the gas 
exchange functions, i.e. oxygenation, carbon dioxide removal, or both. This then 
results in hypoaxemia (the arterial oxygen tension is less than 8.0 kPa) with or 
without hypercapnia (arterial carbon dioxide tension is more than or equal to 6.5 
kPa) [90]. Patients with respiratory failure often require respiratory support, 
especially when simple measures such as supplemental oxygen therapy, secretion 
control, and antibiotic therapy are unsatisfactory. Mechanical ventilation can be 
used as respiratory support. However, the use of mechanical ventilation can cause 
lung injury, which is ascribed to excessive energy delivered to the lung, resulting 
from excessive pressure, volume, or respiratory rate [91]. An ECMO is then 
considered as an attractive alternative way of treating patients with severe 
respiratory failure, in which the gas exchange functions of the lung are expected 
to be taken over by the ECMO so that the lung can rest. Besides that, high airway 
pressure on the patient’s respiratory organs is no longer necessary, preventing 
lung injury. 
Patients with respiratory failure who need an ECMO are generally indicated by a 
reversible pulmonary disease [92]. Acute respiratory distress syndrome (ARDS) 
is a respiratory indication for ECMO treatment, which is also the most widely 
studied. Early trials have demonstrated that ECMOs do not provide greater 
survival in ARDS patients compared to conventional mechanical ventilation 
[93,94]. A study conducted by Suchyta, et al. [95] then found increased survival 
of ARDS patients meeting the blood-gas criteria of ECMOs, which could be due 
to different patient selection, advances in medical technology, and hospital-
specific reasons. A study conducted by Liao, et al. [96] revealed the efficacy of 
7 days of ECMO supplementation for the treatment of ARDS patients caused by 
scrub typhus. Also ECMO was compared with conventional treatment for 
patients (180 in total) with severe adult respiratory failure (CESAR), showing 
that 63% of patients who received ECMO treatment could survive for 6 months 
without disability, in contrast to only 47% for the conventional treatment [97]. 
The success of ECMO in suppressing the mortality rate has also been shown when 
this system was used for treating patients with ARDS during the influenza A 
(H1N1) pandemic in 2009, the avian influenza A (H7N9) pandemic, and for the 
middle east respiratory syndrome (MERS) [98,99]. However, there are multiple 
risk factors in ARDS. Thus, appropriate selection of ARDS patients to be treated 
using an ECMO is an important factor for success. To address this issue, an 
algorithm to guide which ARDS patients should be treated with an ECMO has 
been suggested by Bullen, et al. [100].   
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4.2 ECMO for Cardiac Failure 
There are wide indications for ECMO treatment for patients with cardiac failure, 
which have been comprehensively reviewed by Bermudez, et al. [101]. For 
treating patients with cardiac indications, venoarterial ECMO (VA-ECMO), 
which provides not only respiratory support but also hemodynamic support, is 
recommended to use rather than venovenous ECMO (VV-ECMO), which 
provides no direct hemodynamic support [102]. In addition to providing 
circulatory support, VA-ECMO may provide a bridge to recovery or may be used 
as a bridge to a more durable mechanical solution [103]. However, careful 
consideration of patient selection, the cannulation strategy, and other cardinal 
considerations should be taken when implementing VA-ECMO. 
A medical record review of patients treated with VA-ECMO for cardiac support 
showed a high proportion of survivors, where out of 22 patients, 16 patients 
(72%) survived to hospital discharge [104]. Moreover, 15 discharged patients 
were in good neurological condition. Another medical report by Luo and co-
workers [105] showed that of the 45 patients supported with ECMO during 
cardiac failure, 27 could be successfully weaned. A recent study on VA-ECMO 
for post-cardiotomy cardiogenic shock revealed a significant difference in nadir 
lactate levels between survivors and non-survivors, which could be helpful in 
predicting early survival [106]. Despite the proven efficacy, it should be noted 
that ECMO is suggested to be employed as soon as possible before any organ 
failure develops in cardiac failure patients [105]. For example, a high mortality 
rate was reported when patients were treated with a combination of continuous 
renal replacement therapies (CRRT) and ECMO [107]. In such cases, the acute 
renal failure suffered by the patients may deteriorate the health condition of the 
patient before their condition could be improved through ECMO intervention.  
4.3 ECMO for COVID-19 
Based on the successful experiences on respiratory failure treatment, ECMO has 
been considered as a potential therapy for COVID-19 patients. For centers 
capable of providing ECMO, the World Health Organization recommends the 
treatment of ARDS using ECMO [108]. However, there is also a concern related 
to the limited usefulness of and the lack of evidence for supporting critically ill 
patients suffering from ARDS due to COVID-19 [109]. Initial experiences in 
Japan and South Korea with ECMO in more than 50 COVID-19 cases had 
survivors, though many were still receiving treatment at the time of study. 
Several studies have recently been performed to study the use of ECMO as 
therapy for patients with ARDS induced by COVID-19. The results varied among 
the reported cases. Yang, et al. [110] reported six severely ill patients in Wuhan, 
China who were treated with ECMO. At the endpoint of the study period of 28 
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days, five patients had died, while one patient was still on ECMO. Zhang, et al. 
[111] conducted a single-center, retrospective case series investigation of 221 
hospitalized patients in Wuhan, China, with confirmed COVID-19, from January 
2nd to February 10th, 2020. Out of 55 patients in severe condition, ECMO was 
utilized for ten patients with refractory hypoxemia. At the time of data collection, 
two patients exhibited clinical benefits and were subsequently discharged, five 
patients were still under ECMO support, and the other three were non-survivors. 
Other studies also mention ECMO cases; unfortunately, the outcomes were not 
available [112-114]. A weaning rate of 50% was reported by Haye, et al. [115], 
who studied the impact of a mobile ECMO team during the first three weeks of 
the COVID-19 outbreak in France.  
A more comprehensive investigation based on pool analysis of 331 COVID-19 
cases supported with ECMO showed a mortality rate of 46% (95%CI = 34-59%) 
[116], which was smaller compared to the mortality rate of severely ill COVID-
19 patients who received conventional treatment, around 59-71% [110-117]. 
Based on the abovementioned results, it should be stressed that the efficacy of 
ECMO treatment in COVID-19-induced ADRS conditions is not yet clear. This 
is because several challenging factors affect the success of ECMO. One of the 
important requirements is more data on the death mechanism and disease, from 
which the appropriateness of the use of ECMO to treat COVID-19 patients is 
determined [108]. 
However, more promising results are being reported by researchers. Wang et al. 
[118] reported a COVID-19 patient with cytokine storm who fully recovered 
using ECMO support after four times negative results of nucleic acid testing and 
was then discharged on day 38. Ikuyama, et al. [119] reported the successful 
recovery of a 76-year-old female patient in Matsumoto, Japan from acute 
COVID-19 pneumonia via ECMO treatment. While the use of lopinavir-ritonavir 
and premivir treatment did not show significant benefits, the application of 
ECMO from symptom onset day (SOD) 19 to 31 led to complete recovery. A 
similar successful recovery case was also found in a 45-year old male patient in 
Tokyo, Japan [120]. It was suggested that risk factors, e.g. old age and other 
comorbidities (hypertension, diabetes, and asthma) may correspond to the 
mortality after ECMO treatment rather than ECMO itself [119]. Another report 
indicates that early ECMO treatment could have more considerable benefits than 
that applied after conventional therapies [121]. Since ECMO usage can also 
inflict adverse side effects on patients, judicious selection of patients who 
urgently need ECMO support is necessary to optimize the treatment of COVID-
19 patients with ECMO [99]. 
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5 Conclusions and Future Outlook 
ECMO treatment has great potential to provide sufficient oxygenation for 
respiratory failure patients with decreasing pulmonary function, which 
conventional ventilation can no longer manage. As the key to ECMO, the 
membrane oxygenator must be biocompatible and able to perform efficient gas 
exchange. Research and development have been devoted to finding appropriate 
membrane materials, module types, and flow configurations to achieve these 
goals. Silicones have been long used as membrane material because of their blood 
compatibility and ability to avoid plasma leakage, but they have poor gas 
permeability. Hence, microporous PP membrane oxygenators have then been 
developed. However, the wetting phenomena hinder their use for prolonged 
periods; thus, a modification such as silicone coating is required. In a recent 
development, PMP membrane oxygenators have been fabricated for long-term 
usage. Membrane oxygenators have dramatically evolved, from plate-type and 
spiral-wound-type to HF module with different fiber arrangements and flow 
directions. In addition, surface modification using biocompatible materials has 
also been attempted. It is imperative to consider the mean pore size of the 
membrane oxygenator rather than the maximal pore size since the pores in the 
membrane wall play a more significant role in determining the resistance to 
plasma leakage than the surface pores. Two membranes may have the same 
maximal pore size, but their mean pore differs significantly, leading to a severe 
problem during the ECMO treatment. However, to be applied successfully, an 
adequate preclinical evaluation is needed, including determining surface-active 
species in the patient’s blood, e.g. phospholipid, alcohol, and drug molecules. 
These strategies should be able to minimize the health risk during the ECMO 
treatment. Unfortunately, not all existing studies have addressed them. 
ECMO could provide an alternative solution for treating patients with respiratory 
or cardiac failure. Reported studies have shown that there were improved 
outcomes when using ECMO compared to conventional treatments. However, 
careful consideration should be taken, especially with regard to patient selection. 
ECMO has also been considered to use as therapy for patients with respiratory 
failure induced by COVID-19. Although the effect of ECMO on severely ill 
COVID-19 patients has not yet been established, more cases are continuously 
being reported in which the ECMO treatment exhibited a positive impact on the 
recovery of COVID-19 patients. In this regard, the presence of comorbidities 
should also be taken into account, since they play a significant role in determining 
the mortality rate of COVID-19 patients. After all, COVID-19 is a challenging 
novel disease, where all treatments including ECMO must be performed with 
vital precautions. An effective organization comprising a synergy of the aspects 
of personnel, equipment, facilities, and systems will improve the efficacy of 
ECMO deployment. 
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